Stockreport

Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects [Yahoo! Finance]

Legend Biotech Corporation - American Depositary Shares  (LEGN) 
PDF an Outperform rating on Legend Biotech Corp (NASDAQ:LEGN) and set a $74 price target. The positive stance echoes the superior efficacy data on the company's multiple m [Read more]